Zobrazeno 1 - 10
of 22
pro vyhledávání: '"Marten Hansen"'
Autor:
Huan Zhang, Marten Hansen, Franca di Summa, Marieke von Lindern, Nynke Gillemans, Wilfred F.J. van IJcken, Arthur Flohr Svendsen, Sjaak Philipsen, Bert van der Reijden, Eszter Varga, Emile van den Akker
Publikováno v:
Haematologica, Vol 999, Iss 1 (2024)
Differentiation of induced pluripotent stem cells (iPSCs) into hematopoietic lineages offers great therapeutic potential. During embryogenesis, hemogenic endothelium (HE) gives rise to hematopoietic stem and progenitor cells through the endothelial-t
Externí odkaz:
https://doaj.org/article/844b71922450425d8dc141a667fe69d7
Autor:
Thomas Blom, Rutger Meinsma, Franca di Summa, Emile van den Akker, André B. P. van Kuilenburg, Marten Hansen, Godelieve A. M. Tytgat
Publikováno v:
EJNMMI Research, Vol 11, Iss 1, Pp 1-10 (2021)
Abstract Background The therapeutic use of [131I]meta-iodobenzylguanidine ([131I]MIBG) is often accompanied by hematological toxicity, primarily consisting of severe and persistent thrombocytopenia. We hypothesize that this is caused by selective upt
Externí odkaz:
https://doaj.org/article/e3482717233340d9b6a012d2838da30a
Autor:
Marten Hansen, Eszter Varga, Cathelijn Aarts, Tatjana Wust, Taco Kuijpers, Marieke von Lindern, Emile van den Akker
Publikováno v:
Stem Cell Research, Vol 29, Iss , Pp 232-244 (2018)
Hematopoietic differentiation of human induced pluripotent stem cells (iPSCs) provide opportunities not only for fundamental research and disease modelling/drug testing but also for large-scale production of blood effector cells for future clinical a
Externí odkaz:
https://doaj.org/article/86f71e60eb8b49bdb318c8b5a2c904d2
Publikováno v:
Stem Cell Research, Vol 25, Iss C, Pp 30-33 (2017)
Peripheral blood mononuclear cells were isolated and cultured to a pure pro-EBL population and reprogrammed using episomal plasmids. The pluripotency of transgene-free induced pluripotent stem cell (iPSC) line was verified by the expression of plurip
Externí odkaz:
https://doaj.org/article/9578b562cbe64e20b8d4f4d8804923e2
Autor:
Marten Hansen, Eszter Varga, Tatjana Wüst, Clemens Mellink, Anne-Marie van der Kevie-Kersemaekers, Marieke von Lindern, Emile van den Akker
Publikováno v:
Stem Cell Research, Vol 25, Iss C, Pp 42-45 (2017)
Mobilized peripheral blood (MPB) CD34+ cells were differentiated to CD34+/CD41+ megakaryoblasts. Cells were sorted to obtain a pure megakaryoblast population which was reprogrammed with a hOKSM self-silencing polycistronic lentiviral vector. Resultin
Externí odkaz:
https://doaj.org/article/f717d64c255d4e09b6b8655e1b9d9213
Autor:
Marten Hansen, Eszter Varga, Tatjana Wüst, Clemens Mellink, Anne-Marie van der Kevie-Kersemaekers, Anne E. Marneth, Marieke von Lindern, Bert van der Reijden, Emile van den Akker
Publikováno v:
Stem Cell Research, Vol 25, Iss C, Pp 34-37 (2017)
Peripheral blood mononuclear cells were isolated from an individual harboring a heterozygous c.859C → T p.Q287* mutation in GFI1B, causing an autosomal dominant bleeding disorder, platelet type, 17 (BDPLT17). PBMCs were differentiated to erythrobla
Externí odkaz:
https://doaj.org/article/91a2cfd943dd436f9e9a8fa9f4e6c4e8
Autor:
Rinske van Oorschot, Marten Hansen, Johanna M. Koornneef, Anna E. Marneth, Saskia M. Bergevoet, Maaike G.J.M. van Bergen, Floris P.J. van Alphen, Carmen van der Zwaan, Joost H.A. Martens, Michiel Vermeulen, Pascal W.T.C. Jansen, Marijke P.A. Baltissen, Britta A.P. Laros-van Gorkom, Hans Janssen, Joop H. Jansen, Marieke von Lindern, Alexander B. Meijer, Emile van den Akker, Bert A. van der Reijden
Publikováno v:
Haematologica, Vol 104, Iss 7 (2019)
Dominant-negative mutations in the transcription factor Growth Factor Independence-1B (GFI1B), such as GFI1BQ287*, cause a bleeding disorder characterized by a plethora of megakaryocyte and platelet abnormalities. The deregulated molecular mechanisms
Externí odkaz:
https://doaj.org/article/fa460826edfb42dbb79b809d6ce5fa66
Autor:
Marten Hansen, Sabrina Zeddies, Marjolein Meinders, Franca di Summa, Ewa Rollmann, Floris P.J. van Alphen, Arjan J. Hoogendijk, Kat S. Moore, Melanie Halbach, Laura Gutiérrez, Maartje van den Biggelaar, Daphne C. Thijssen-Timmer, Georg W.J. Auburger, Emile van den Akker, Marieke von Lindern
Publikováno v:
International Journal of Molecular Sciences, Vol 21, Iss 3, p 967 (2020)
Megakaryopoiesis is the process during which megakaryoblasts differentiate to polyploid megakaryocytes that can subsequently shed thousands of platelets in the circulation. Megakaryocytes accumulate mRNA during their maturation, which is required for
Externí odkaz:
https://doaj.org/article/62f2d868f0204d978b42a030e22eb427
Autor:
Maartje W. Rohaan, Troels H. Borch, Joost H. van den Berg, Özcan Met, Rob Kessels, Marnix H. Geukes Foppen, Joachim Stoltenborg Granhøj, Bastiaan Nuijen, Cynthia Nijenhuis, Inge Jedema, Maaike van Zon, Saskia Scheij, Jos H. Beijnen, Marten Hansen, Carlijn Voermans, Inge M. Noringriis, Tine J. Monberg, Rikke B. Holmstroem, Lidwina D.V. Wever, Marloes van Dijk, Lindsay G. Grijpink-Ongering, Ludy H.M. Valkenet, Alejandro Torres Acosta, Matthias Karger, Jessica S.W. Borgers, Renske M.T. ten Ham, Valesca P. Retèl, Wim H. van Harten, Ferry Lalezari, Harm van Tinteren, Astrid A.M. van der Veldt, Geke A.P. Hospers, Marion A.M. Stevense-den Boer, Karijn P.M. Suijkerbuijk, Maureen J.B. Aarts, Djura Piersma, Alfons J.M. van den Eertwegh, Jan-Willem B. de Groot, Gerard Vreugdenhil, Ellen Kapiteijn, Marye J. Boers-Sonderen, W. Edward Fiets, Franchette W.P.J. van den Berkmortel, Eva Ellebaek, Lisbet R. Hölmich, Alexander C.J. van Akkooi, Winan J. van Houdt, Michel W.J.M. Wouters, Johannes V. van Thienen, Christian U. Blank, Aafke Meerveld-Eggink, Sebastian Klobuch, Sofie Wilgenhof, Ton N. Schumacher, Marco Donia, Inge Marie Svane, John B.A.G. Haanen
Publikováno v:
New England Journal of Medicine, 387(23), 2113-2125. MASSACHUSETTS MEDICAL SOC
The New England Journal of Medicine, 387, 2113-2125
New England journal of medicine, 387(23), 2113-2125. Massachussetts Medical Society
Rohaan, M W, Borch, T H, Van Den Berg, J H, Met, Ö, Kessels, R, Geukes Foppen, M H, Stoltenborg Granhøj, J, Nuijen, B, Nijenhuis, C, Jedema, I, Van Zon, M, Scheij, S, Beijnen, J H, Hansen, M, Voermans, C, Noringriis, I M, Monberg, T J, Holmstroem, R B, Wever, L D V, Van Dijk, M, Grijpink-Ongering, L G, Valkenet, L H M, Torres Acosta, A, Karger, M, Borgers, J S W, Ten Ham, R M T, Retèl, V P, Van Harten, W H, Lalezari, F, Van Tinteren, H, Van Der Veldt, A A M, Hospers, G A P, Stevense-Den Boer, M A M, Suijkerbuijk, K P M, Aarts, M J B, Piersma, D, Van Den Eertwegh, A J M, De Groot, J W B, Vreugdenhil, G, Kapiteijn, E, Boers-Sonderen, M J, Fiets, W E, Van Den Berkmortel, F W P J, Ellebaek, E, Hölmich, L R, Van Akkooi, A C J, Van Houdt, W J, Wouters, M W J M, Van Thienen, J V, Blank, C U, Meerveld-Eggink, A, Klobuch, S, Wilgenhof, S, Schumacher, T N, Donia, M, Svane, I M & Haanen, J B A G 2022, ' Tumor-Infiltrating Lymphocyte Therapy or Ipilimumab in Advanced Melanoma. ', New England Journal of Medicine, vol. 387, no. 23, pp. 2113-2125 . https://doi.org/10.1056/NEJMoa2210233
The New England journal of medicine, 387(23), 2113-2125. Massachussetts Medical Society
New England Journal of Medicine, 387(23), 2113-2125. MASSACHUSETTS MEDICAL SOCIETY
The New England Journal of Medicine, 387, 23, pp. 2113-2125
The New England Journal of Medicine, 387, 2113-2125
New England journal of medicine, 387(23), 2113-2125. Massachussetts Medical Society
Rohaan, M W, Borch, T H, Van Den Berg, J H, Met, Ö, Kessels, R, Geukes Foppen, M H, Stoltenborg Granhøj, J, Nuijen, B, Nijenhuis, C, Jedema, I, Van Zon, M, Scheij, S, Beijnen, J H, Hansen, M, Voermans, C, Noringriis, I M, Monberg, T J, Holmstroem, R B, Wever, L D V, Van Dijk, M, Grijpink-Ongering, L G, Valkenet, L H M, Torres Acosta, A, Karger, M, Borgers, J S W, Ten Ham, R M T, Retèl, V P, Van Harten, W H, Lalezari, F, Van Tinteren, H, Van Der Veldt, A A M, Hospers, G A P, Stevense-Den Boer, M A M, Suijkerbuijk, K P M, Aarts, M J B, Piersma, D, Van Den Eertwegh, A J M, De Groot, J W B, Vreugdenhil, G, Kapiteijn, E, Boers-Sonderen, M J, Fiets, W E, Van Den Berkmortel, F W P J, Ellebaek, E, Hölmich, L R, Van Akkooi, A C J, Van Houdt, W J, Wouters, M W J M, Van Thienen, J V, Blank, C U, Meerveld-Eggink, A, Klobuch, S, Wilgenhof, S, Schumacher, T N, Donia, M, Svane, I M & Haanen, J B A G 2022, ' Tumor-Infiltrating Lymphocyte Therapy or Ipilimumab in Advanced Melanoma. ', New England Journal of Medicine, vol. 387, no. 23, pp. 2113-2125 . https://doi.org/10.1056/NEJMoa2210233
The New England journal of medicine, 387(23), 2113-2125. Massachussetts Medical Society
New England Journal of Medicine, 387(23), 2113-2125. MASSACHUSETTS MEDICAL SOCIETY
The New England Journal of Medicine, 387, 23, pp. 2113-2125
Item does not contain fulltext BACKGROUND: Immune checkpoint inhibitors and targeted therapies have dramatically improved outcomes in patients with advanced melanoma, but approximately half these patients will not have a durable benefit. Phase 1-2 tr
Autor:
Marten Hansen, André B.P. van Kuilenburg, Thomas Blom, Emile van den Akker, Rutger Meinsma, Franca di Summa, Godelieve A.M. Tytgat
Publikováno v:
EJNMMI research, 11(1):81. Springer Berlin
EJNMMI Research, Vol 11, Iss 1, Pp 1-10 (2021)
EJNMMI Research
EJNMMI Research, Vol 11, Iss 1, Pp 1-10 (2021)
EJNMMI Research
Background The therapeutic use of [131I]meta-iodobenzylguanidine ([131I]MIBG) is often accompanied by hematological toxicity, primarily consisting of severe and persistent thrombocytopenia. We hypothesize that this is caused by selective uptake of MI